Condition
Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Not Yet Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06838429Not Yet RecruitingPrimary
PARPi and Ovarian Cancer Survival
NCT00189371Phase 3TerminatedPrimary
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Showing all 2 trials